Physical characterization and formulation development of a recombinant pneumolysoid protein-based pneumococcal vaccine

Journal of Pharmaceutical Sciences

Volumn 102, Issue 2, 2013, Pages 387-400

  Hu, Lei ^a   Joshi, Sangeeta B ^a   Liyanage, Mangala Roshan ^a,c   Pansalawatta, Mekala ^a   Alderson, Mark R ^b   Tate, Andrea ^b   Robertson, George ^b   Maisonneuve, Jeff ^b   Volkin, David B ^a   Middaugh, C Russell ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b PATH   (United States)

^c Dendreon   (United States)

Author keywords

Formulation; Physical characterization; Stability; Vaccine adjuvants; Vaccines

Indexed keywords

ALUMINUM HYDROXIDE; ANTIGEN; PNEUMOCOCCUS VACCINE; PNEUMOLYSIN; SUCROSE; TREHALOSE;

ADSORPTION; ARTICLE; CIRCULAR DICHROISM; FLUORESCENCE SPECTROSCOPY; LIGHT SCATTERING; STREPTOCOCCUS PNEUMONIAE; TRANSITION TEMPERATURE; ULTRAVIOLET SPECTROSCOPY;

EID: 84872502459     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23375     Document Type: Article

References (36)

1. Gray BM, Converse GM, Dillon HC. 1980. Epidemiologic studies of Streptococcus pneumoniae in infants: Acquisition, carriage, and infection during the first 24 months of life. J Infect Dis 142(6):923-933.
2. Johnston Jr RB. 1991. Pathogenesis of pneumococcal pneumonia. Rev Infect Dis 13(Suppl 6):S509-S517.
3. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T. 2009. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: Global estimates. Lancet 374(9693):893-902.
4. Black S, Eskola J, Whitney C, Shinefield H. 2008. Vaccines. 5 ed. Philadelphia, Pennsylvania: W.B. Saunders Company, pp 531-567.
5. Jackson LA, Neuzil KM. 2008. Vaccines. 5 ed. Philadelphia, Pennsylvania: W.B. Saunders Company, pp 569-604.
6. Iyer V, Hu L, Liyanage MR, Esfandiary R, Reinisch C, Meinke A, Maisonneuve J, Volkin DB, Joshi SB, Middaugh CR. 2012. Preformulationi characterization of an aluminum salt-adjuvanted trivalent recombinant protein-based vaccine candidate against Streptococcus pneumoniae. J Pharm Sci 101(9):3078-3090.
7. Rubins JB, Janoff EN. 1998. Pneumolysin: A multifunctional pneumococcal virulence factor. J Lab Clin Med 131(1):21-27.
8. Jedrzejas MJ. 2001. Pneumococcal virulence factors: Structure and function. Microbiol Mol Biol Rev 65(2):187-207.
9. Mitchell A, Mitchell T. 2010. Streptococcus pneumoniae: Virulence factors and variation. Clin Microbiol Infect 16(5):411-418.
10. Molloy S. 2010. Bacterial pathogenicity: Pneumolysin: Stimulating protection. Nat Rev Microbiol 9(1):4-4.
11. Paton JC, Lock RA, Hansman DJ. 1983. Effect of immunization with pneumolysin on survival time of mice challenged with Streptococcus pneumoniae. Infect Immun 40(2):548-552.
12. Lock RA, Hansman D, Paton JC. 1992. Comparative efficacy of autolysin and pneumolysin as immunogens protecting mice against infection by Streptococcus pneumoniae. Microb Pathog 12(2):137-143.
13. Alexander JE, Lock RA, Peeters C, Poolman JT, Andrew PW, Mitchell TJ, Hansman D, Paton JC. 1994. Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae. Infect Immun 62(12):5683-5688.
14. Paton JC, Ferrante A. 1983. Inhibition of human polymorphonuclear leukocyte respiratory burst, bactericidal activity, and migration by pneumolysin. Infect Immunity 41(3):1212-1216.
15. Ferrante A, Rowan-Kelly B, Paton JC. 1984. Inhibition of in vitro human lymphocyte response by the pneumococcal toxin pneumolysin. Infect Immun 46(2):585-589.
16. Kirkham LA, Kerr AR, Douce GR, Paterson GK, Dilts DA, Liu DF, Mitchell TJ. 2006. Construction and immunological characterization of a novel nontoxic protective pneumolysin mutant for use in future pneumococcal vaccines. Infect Immun 74(1):586-593.
17. Oloo EO, Yethon JA, Ochs MM, Carpick B, Oomen R. 2011. Structure-guided antigen engineering yields pneumolysin mutants suitable for vaccination against pneumococcal disease. J Biol Chem 286(14):12133.
18. Soltani CE, Hotze EM, Johnson AE, Tweten RK. 2007. Specific protein-membrane contacts are required for prepore and pore assembly by a cholesterol-dependent cytolysin. J Biol Chem 282(21):15709-15716.
19. Farrand AJ, LaChapelle S, Hotze EM, Johnson AE, Tweten RK. 2010. Only two amino acids are essential for cytolytic toxin recognition of cholesterol at the membrane surface. Proc Natl Acad Sci USA 107(9):4341-4346.
20. Mitchell LM, King J, Hale J, Tweten R, Briles D. 2011. Protective immune responses to Streptococcus pneumoniae pneumolysoids. New Orleans, Louisiana: American Society of Microbiology.
21. Mann B, Tweten R, Gao G, Thornton J, Heath R, Maisonneuve J, Tuomanen E. 2012. Broadly protective protein based pneumococcal vaccine comprised of pneumolysin toxoid-CbpA peptide fusion. Iguacu Falls, Brazil: International Symposium on Pneumococci and Pneumococcal Diseases.
22. Wilson-Welder JH, Torres MP, Kipper MJ, Mallapragada SK, Wannemuehler MJ, Narasimhan B. 2009. Vaccine adjuvants: Current challenges and future approaches. J Pharm Sci 98(4):1278-1316.
23. Iyer V, Liyanage MR, Shoji Y, Chichester JA, Jones RM, Yusibov V, Joshi SB, Middaugh CR. 2012. Formulation development of a plant-derived h1n1 influenza vaccine containing purified recombinant hemagglutinin antigen. Hum Vaccin Immunotherapeut 8(4):453-464.
24. Kueltzo LA, Ersoy B, Ralston JP, Middaugh CR. 2003. Derivative absorbance spectroscopy and protein phase diagrams as tools for comprehensive protein characterization: A bGCSF case study. J Pharm Sci 92(9):1805-1820.
25. Maddux NR, Joshi SB, Volkin DB, Ralston JP, Middaugh CR. 2011. Multidimensional methods for the formulation of biopharmaceuticals and vaccines. J Pharm Sci 100(10):4171-4197.
26. Hu L, Olsen CM, Maddux NR, Joshi SB, Volkin DB, Middaugh CR. 2011. Investigation of protein conformational stability employing a multimodal spectrometer. Anal Chem 83(24):9399-9405.
27. Maddux NR, Rosen IT, Hu L, Olsen CM, Volkin DB, Middaugh CR. 2012. An improved methodoloy for multidimensional hig-throughput preformulation characterization of protein conformational stabiliity. J Pharm Sci 101(6):2017-2024.
28. Kim JH, Iyer V, Joshi SB, Volkin DB, Middaugh CR. 2012. Improved data visualization techniques for analyzing macromolecule structrual changes. Protein Sci 21(10):1540-1553.
29. Böhm G, Muhr R, Jaenicke R. 1992. Quantitative analysis of protein far UV circular dichroism spectra by neural networks. Protein Eng 5(3):191-195.
30. Kuo J, Douglas M, Ree HK, Lindberg AA. 1995. Characterization of a recombinant pneumolysin and its use as a protein carrier for pneumococcal type 18C conjugate vaccines. Infect Immun 63(7):2706-2713.
31. Kaushik JK, Bhat R. 2003. Why is trehalose an exceptional protein stabilizer? J Biol Chem 278(29):26458-26465.
32. Kendrick BS, Chang BS, Arakawa T, Peterson B, Randolph TW, Manning MC, Carpenter JF. 1997. Preferential exclusion of sucrose from recombinant interleukin-1 receptor antagonist: Role in restricted conformational mobility and compaction of native state. Proc Natl Acad Sci USA 94(22):11917.
33. Ohtake S, Wang YJ. 2011. Trehalose: Current use and future applications. J Pharm Sci 100(6):2020-2053.
34. Wang W, Nema S, Teagarden D. 2010. Protein aggregation-Pathways and influencing factors. Int J Pharm 390(2):89-99.
35. Costantino HR, Carrasquillo KG, Cordero RA, Mumenthaler M, Hsu CC, Griebenow K. 1998. Effect of excipients on the stability and structure of lyophilized recombinant human growth hormone. J Pharm Sci 87(11):1412-1420.
36. Cleland JL, Lam X, Kendrick B, Yang J, Yang T, Overcashier D, Brooks D, Hsu C, Carpenter JF. 2001. A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody. J Pharm Sci 90(3):310-321.